Ongoing surveillance of patients with a first primary melanoma-in-situ is a good idea.
The risk for developing a second invasive melanoma after a first invasive melanoma has been estimated to be about 3% at 10 years. The risk for developing a melanoma after a melanoma-in-situ (MIS) has not been fully explored, and it has implications for the post-melanoma surveillance of the increasing number of patients with MIS.
Using data on patients registered in the Surveillance, Epidemiology, and End Results (SEER) program between 1973 and 2011, these authors compared risk for subsequent melanoma in patients whose first cancer was MIS and those whose first cancer was invasive melanoma. They identified 55,661 patients with MIS and 112,613 with invasive melanoma as the first primary cancer. In this total cohort of 168,274 patients, 10,876 …
Reviewing Author
DisclosuresConsultant / advisory board Lubax; WorldCare Clinical
EquityLubax
Grant / Research support NIH; Department of Defense; American Skin Association; Piramal
Editorial boardsBritish Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology
Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)
DisclosuresConsultant / advisory board Lubax; WorldCare Clinical
EquityLubax
Grant / Research support NIH; Department of Defense; American Skin Association; Piramal
Editorial boardsBritish Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology
Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)